| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a compound which provides EP3 receptor antagonism, and a pharmaceutical composition which contains the compound and is for prevention against and treatment of prostaglandin mediated disorders. <P>SOLUTION: There is disclosed the compound represented by general formula (I), where R<SP POS="POST">1</SP>and R<SP POS="POST">2</SP>are a hydrogen atom, a lower alkyl group, a lower haloalkyl group, a lower alkoxy group, or a halogen atom, R<SP POS="POST">3</SP>is a monocyclic or bicyclic aromatic ring or heterocyclic ring, or a cyclo ring, R<SP POS="POST">4</SP>is a monocyclic or bicyclic aromatic ring or heterocyclic ring, X is -CH<SB POS="POST">2</SB>- or a carbon atom having a lower alkyl group, Y is -CH<SB POS="POST">2</SB>CH<SB POS="POST">2</SB>-(CH<SB POS="POST">2</SB>)m- or -CR<SB POS="POST">5</SB>=CR<SB POS="POST">6</SB>-(CH<SB POS="POST">2</SB>)m- (R<SB POS="POST">5</SB>and R<SB POS="POST">6</SB>may be identical or different and a hydrogen atom or a halogen atom), -O-CH<SB POS="POST">2</SB>-(CH<SB POS="POST">2</SB>)m-, (cyclo ring (1-5 carbons))-(CH<SB POS="POST">2</SB>)m-, or (monocyclic or bicyclic aromatic ring)-(CH<SB POS="POST">2</SB>)m-, where m is 0-5, Z is a bond or -SO<SB POS="POST">2</SB>-, and n is 0-5. <P>COPYRIGHT: (C)2013,JPO&INPIT |
